ArticleEJNMMI research2025
Comparing three methodologies for network analysis of human [
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDynamic whole-body PET and total-body PET both supply large datasets that include multiple organs, opening the opportunity to study systems biology via appropriate analysis. Network analysis, commonly used with brain imaging, is applied here with whole-body PET to compare data from different tissues and subjects before and after precipitating a pharmacokinetic drug-drug interaction. This is done with [11C]glyburide PET, a radiotracer whose tissue distribution is mediated by organic anion-transporting polypeptides (OATP) transporter function. OATPs control the uptake of drugs, primarily into the liver. We examine three methods of network analysis to evaluate the effort, efficacy, and potential applications for further research use. This was performed with 22 dynamic [11C]glyburide whole-body PET scans of healthy humans. This includes 13 baseline scans, and 9 after infusion of rifampicin, a potent OATP inhibitor. All methods use Pearson correlation coefficient. The first method generates “d-networks” using dynamic data from one region. The second method generates “s-networks” using static data from multiple regions, but not all regions. The final method generates “ΔPCC networks” with static data from all regions. The first two methods compare subjects, whereas the third compares regions.
resultsThe d-network differentiates control and rifampicin subjects within the primary region of interest, the liver, but the differentiation is not complete, and there is still some correlation across subjects (r>0.65, p<0.05). The s-network completely distinguishes trial groups but requires removing anomalous data from consideration (r>0.65, p<0.05). Because d- and s-networks require selecting which regions are included, they are informed methods. In contrast, the ΔPCC networks are uninformed. This method utilises all data and still highlights significant regional variations between the two groups, such as in the liver, while remaining robust to confounding variation (|ΔPCC|>0.18, p<0.05).
conclusionsAll three methods of network analysis with whole-body PET were successful at identifying key information in the dataset. Each method required different levels of processing and interpretation, making them applicable in different scenarios depending on whether the PET data is dynamic or static, if the kinetics in regions of interest are well understood, and whether the study is focused on comparing between treatment groups or regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.